Citadel Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-226,600
| Closed | -$5.46M | – | 15737 |
|
|
2023
Q1 | $5.46M | Sell |
226,600
-144,500
| -39% | -$1.81M | ﹤0.01% | 3660 |
|
|
2022
Q4 | $3.92M | Buy |
371,100
+199,000
| +116% | +$1.61M | ﹤0.01% | 4271 |
|
|
2022
Q3 | $774K | Buy |
172,100
+7,400
| +4% | +$33.7K | ﹤0.01% | 7548 |
|
|
2022
Q2 | $659K | Buy |
164,700
+96,300
| +141% | +$457K | ﹤0.01% | 8030 |
|
|
2022
Q1 | $501K | Sell |
68,400
-30,700
| -31% | -$184K | ﹤0.01% | 9396 |
|
|
2021
Q4 | $557K | Buy |
99,100
+51,100
| +106% | +$324K | ﹤0.01% | 9435 |
|
|
2021
Q3 | $307K | Sell |
48,000
-61,500
| -56% | -$395K | ﹤0.01% | 11034 |
|
|
2021
Q2 | $923K | Buy |
109,500
+8,200
| +8% | +$66.2K | ﹤0.01% | 8576 |
|
|
2021
Q1 | $1.06M | Buy |
101,300
+54,700
| +117% | +$770K | ﹤0.01% | 7961 |
|
|
2020
Q4 | $789K | Sell |
46,600
-17,300
| -27% | -$259K | ﹤0.01% | 7285 |
|
|
2020
Q3 | $820K | Sell |
63,900
-1,000
| -2% | -$12.6K | ﹤0.01% | 6387 |
|
|
2020
Q2 | $916K | Buy |
64,900
+21,800
| +51% | +$275K | ﹤0.01% | 5996 |
|
|
2020
Q1 | $397K | Buy |
43,100
+6,700
| +18% | +$86.3K | ﹤0.01% | 6846 |
|
|
2019
Q4 | $542K | Buy |
+36,400
| New | +$324K | ﹤0.01% | 6689 |
|
Other funds holding PRVB
Citadel Advisors's PRVB Position: Q2 2023 in Review
Citadel Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 520,560 shares — an estimated $12.5M sold.
Citadel Advisors first reported a position in PRVB in Q1 2019 and held it in 13 quarters. The position peaked at $12.5M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Citadel Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 520,560 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $12.5M.
- Citadel Advisors first reported a position in Provention Bio, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
- Citadel Advisors's Provention Bio, Inc. Common Stock position peaked at $12.5M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.